{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:18:17Z","timestamp":1725927497905},"posted":{"date-parts":[[2024,8,26]]},"group-title":"In Review","reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,7,13]]},"abstract":"<title>Abstract<\/title>\n        <p>Background\n Primary brain tumor patients present with a unique trajectory of illness, with an uncertain prognosis, a rapid decline in physical functioning and a significant worsening of quality of life.\nMethods\n  <bold>The<\/bold> EORTC QLQ C30 &amp; EORTC BN 20 questionnaires were used to assess quality of life and symptom burden in patients with primary brain tumors. The scores were analysed using SPSS statistical software.\nResults\n One hundred patients\u201461 males and 39 females\u2014with radiological or histo-pathological diagnoses of primary brain tumors were included. Seizures (38%) were the most common presenting symptom (38%), followed by headache (18%), loss of consciousness (13%), focal neurological deficit (9%) and blurring of vision (8%). The mean quality of life at baseline was 78.29, with a standard deviation of 9.67 on a scale of 0 to 100, and the brain tumor-specific symptom burden score was 46.9, with a standard deviation of 17.95 on a scale of 0 to 100. There was a significant difference in the global health status score between the first visit and third visit, i.e., at three months (p value\u2009=\u20090.03).\nConclusion\n Primary brain tumors are often aggressive and deemed incurable. Unaddressed symptoms such as fatigue and insomnia, future uncertainties and decreased social functioning are widely prevalent in such patients. The integration of palliative care in the treatment course is important to ensure good quality of life in such patients.<\/p>","DOI":"10.21203\/rs.3.rs-4735996\/v1","type":"posted-content","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T14:01:26Z","timestamp":1724680886000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of symptom burden and quality of life in patients with primary brain tumors receiving palliative care in a tertiary cancer care centre"],"prefix":"10.21203","author":[{"given":"Pratyasa","family":"Padhi","sequence":"first","affiliation":[{"name":"Dr BRA IRCH AIIMS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishkarsh","family":"Gupta","sequence":"additional","affiliation":[{"name":"Dr BRA IRCH AIIMS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachidanand Jee","family":"Bharati","sequence":"additional","affiliation":[{"name":"Dr BRA IRCH AIIMS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Garg","sequence":"additional","affiliation":[{"name":"Dr BRA IRCH AIIMS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Mishra","sequence":"additional","affiliation":[{"name":"Dr BRA IRCH AIIMS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushma","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"Dr BRA IRCH AIIMS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haresh","family":"KP","sequence":"additional","affiliation":[{"name":"Dr BRA IRCH AIIMS"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[{"name":"Dr BRA IRCH AIIMS"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"author":"Cancer [Internet]","key":"ref1","unstructured":"Cancer [Internet].[cited2023Jul18].Availablefrom:https:\/\/www.who.int\/health-topics\/cancer#tab=tab_1"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"e205-212","DOI":"10.1016\/S1470-2045(14)70115-9","article-title":"The growing burden of cancer in India: epidemiology and social context","volume":"15","author":"Mallath MK","year":"2014","unstructured":"Mallath MK, Taylor DG, Badwe R A,Rath GK, Shanta V, Pramesh CS, et al. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol. 2014;15(6):e205-212.","journal-title":"Lancet Oncol"},{"issue":"Suppl2","key":"ref3","first-page":"ii12","article-title":"Brain tumours: incidence, survival, and aetiology","volume":"75","author":"McKinney P","unstructured":"McKinney P. Brain tumours: incidence, survival, and aetiology. J Neurol Neurosurg Psychiatry.2004Jun;75(Suppl2): ii12\u20137.","journal-title":"J Neurol Neurosurg Psychiatry.2004Jun"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert MR","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1547-5069.2004.04038.x","article-title":"Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors","volume":"36","author":"Armstrong TS","year":"2004","unstructured":"Armstrong TS, Cohen MZ, Eriksen LR, Hickey JV. Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. J Nurs Scholarsh. 2004;36(3):197\u2013206.","journal-title":"J Nurs Scholarsh"},{"issue":"Suppl 2","key":"ref6","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/nov267","article-title":"Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report","volume":"18","author":"Armstrong TS","year":"2016","unstructured":"Armstrong TS, Bishof AM, Brown PD, Klein M, Taphoorn MJB, Theodore-Oklota C. Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report. Neuro Oncol. 2016;18 Suppl 2: ii1\u201312.","journal-title":"Neuro Oncol"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Analysis of health-related quality of life in patients with brain tumors prior and subsequent to radiotherapy [Internet]. [cited 2022 Oct 30]. Available from: https:\/\/www.spandidos-publications.com\/ol\/14\/2\/1841","DOI":"10.3892\/ol.2017.6310"},{"issue":"8","key":"ref8","first-page":"10","article-title":"Cognitive Rehabilitation and Problem- Solving to Improve Quality of Life of Patients with Primary Brain Tumors: A Pilot Study","volume":"6","author":"Locke DEC","year":"2008","unstructured":"Locke DEC, Cerhan JH, Wu W, Malec JF, Clark MM, Rummans TA, et al. Cognitive Rehabilitation and Problem- Solving to Improve Quality of Life of Patients with Primary Brain Tumors: A Pilot Study. THE JOURNAL OF SUPPORTIVE ONCOLOGY. 2008;6(8):10.","journal-title":"THE JOURNAL OF SUPPORTIVE ONCOLOGY"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1215\/15228517-2008-093","article-title":"Quality of life in adults with brain tumors: current knowledge and future directions","volume":"11","author":"Liu R","year":"2009","unstructured":"Liu R, Page M, Solheim K, Fox S, Chang SM. Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol. 2009;11(3):330\u20139.","journal-title":"Neuro Oncol"},{"issue":"6","key":"ref10","first-page":"1709","article-title":"End-of-Life Care, and Advance Care Planning in Neuro-oncology","volume":"23","author":"Walbert T","year":"2017","unstructured":"Walbert T. Palliative Care, End-of-Life Care, and Advance Care Planning in Neuro-oncology. CONTINUUM: Lifelong Learning in Neurology. 2017;23(6):1709.","journal-title":"CONTINUUM: Lifelong Learning in Neurology"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Neuroophthalmological management of optic pathway gliomas in: Neurosurgical Focus Volume 23 Issue 5 (2007) Journals [Internet]. [cited 2022 Nov 22]. Available from: https:\/\/thejns.org\/focus\/view\/journals\/neurosurg-focus\/23\/5\/foc-07_11_e1.xml","DOI":"10.3171\/FOC-07\/11\/E1"},{"year":"2014","author":"Rooney AG","key":"ref12","unstructured":"Rooney AG, Netten A, McNamara S, Erridge S, Peoples S, Whittle I, et al. Assessment of a brain-tumour- specific Patient Concerns Inventory in the neuro-oncology clinic. Support Care Cancer. 2014Apr 1;22(4):1059\u201369."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4735996\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4735996\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:12:07Z","timestamp":1725891127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-4735996\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":12,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-4735996\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,8,26]]},"subtype":"preprint"}}